Anidulafungin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Changed protection level for "Anidulafungin" ([Edit=Allow only autoconfirmed users] (expires 04:10, 23 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 04:10, 23 January 2014 (UTC))))
No edit summary
Line 1: Line 1:
{{drugbox
__NOTOC__
| IUPAC_name =  
{{Anidulafungin}}
| image = Anidulafungin.svg
'''''For patient information, click <u>[[Anidulafungin (patient information)|here]]</u>'''''.
| width = 300px
 
| CAS_number = 166663-25-8
{{CMG}}; {{AE}} {{AZ}}
| ATC_prefix = J02
 
| ATC_suffix = AX06
==Overview==
| ATC_supplemental =  
 
| PubChem = 166548
==Category==
| DrugBank = APRD01301
 
| C=58 | H=73 | N=7 | O=17
==US Brand Names==
| molecular_weight = 1140.24 g/mol
 
| bioavailability =
==FDA Package Insert==
| protein_bound = 84%
 
| metabolism =
'''  [[Anidulafungin description|Description]]'''
| elimination_half-life = 40-50 hours
'''| [[Anidulafungin clinical pharmacology|Clinical Pharmacology]]'''
| pregnancy_category =
'''| [[Anidulafungin microbiology|Microbiology]]'''
| legal_status =
'''| [[Anidulafungin indications and usage|Indications and Usage]]'''
| routes_of_administration =
'''| [[Anidulafungin contraindications|Contraindications]]'''
}}
'''| [[Anidulafungin warnings and precautions|Warnings and Precautions]]'''
'''Anidulafungin''' or '''Eraxis''' is an anti-fungal drug manufactured by [[Pfizer]] that gained approval by the [[Food and Drug Administration]] (FDA) in February 21, 2006 [http://www.fda.gov/bbs/topics/news/2006/NEW01321.html]; it was previously known as LY303366.  There is preliminary evidence that it has a similar safety profile to [[caspofungin]].  It has proven efficacy against oesophageal candidiasis, but its main utility will probably be in invasive ''[[Candida (genus)|Candida]]'' infection; it will probably also have application in treating invasive [[Aspergillus]] infection.  It is a member of the class of anti-fungal drugs known as the [[echinocandin]]s: its mechanism of action is by inhibition of (1→3)[[β-D-glucan]] synthase, which is an important component of the fungal cell wall.
'''| [[Anidulafungin adverse reactions|Adverse Reactions]]'''
'''| [[Anidulafungin drug interactions|Drug Interactions]]'''
'''| [[Anidulafungin overdosage|Overdosage]]'''
'''| [[Anidulafungin clinical studies|Clinical Studies]]'''
'''| [[Anidulafungin dosage and administration|Dosage and Administration]]'''
'''| [[Anidulafungin how supplied|How Supplied]]'''
'''| [[Anidulafungin labels and packages|Labels and Packages]]'''
 
==Mechanism of Action==


==References==
==References==
* {{cite journal | author=Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T | title=Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia | journal=Antimicrob Agents Chemother | year=2004 | volume=48 | issue=6 | pages=2021&ndash;4 }}
* {{cite journal | author=Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ | title=In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole | journal=J Clin Microbiol | year=2005 | volume=43 | issue=11 | pages=5425&ndash;7 }}
* {{cite journal | author=Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP | title=Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis | journal=Antimicrob Agents Chemother | year=2005 | volume=49 | issue=11 | pages=4795&ndash;7 }}
{{Antifungals}}


[[Category:Antifungals]]
{{Reflist|2}}


[[Category:Antibiotics]]


{{antimicrobial-stub}}
[[Category:Wikinfect]]
{{WikiDoc Help Menu}}

Revision as of 06:09, 9 January 2014

Anidulafungin
Eraxis® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

For patient information, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overview

Category

US Brand Names

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

References

Retrieved from "https://www.wikidoc.org/index.php?title=Anidulafungin&oldid=929591"